Linker Information

General Information of This Linker

Linker ID	LIN0MTORH
Linker Name	Acetamide-PEG4-Val-Ala-PABA
Linker Type	Cathepsin-cleavable linker
Antibody-Linker Relation	Cleavable
Structure
Structure	3D MOL		2D MOL
Formula	C28H45IN4O9
Isosmiles	CC(NC(=O)C(NC(=O)CCOCCOCCOCCOCCNC(=O)CI)C(C)C)C(=O)Nc1ccc(CO)cc1
InChI	InChI=1S/C28H45IN4O9/c1-20(2)26(28(38)31-21(3)27(37)32-23-6-4-22(19-34)5-7-23)33-24(35)8-10-39-12-14-41-16-17-42-15-13-40-11-9-30-25(36)18-29/h4-7,20-21,26,34H,8-19H2,1-3H3,(H,30,36)(H,31,38)(H,32,37)(H,33,35)
InChIKey	IKPMUMLEBHHRSL-UHFFFAOYSA-N
Pharmaceutical Properties	Molecule Weight	708.591	Polar area	173.55
	Complexity	42	xlogp Value	0.7706
	Heavy Count	42	Rot Bonds	23
	Hbond acc	9	Hbond Donor	5

Each Antibody-drug Conjugate Related to This Linker

Full Information of The Activity Data of The ADC(s) Related to This Linker

Trastuzumab-SG3227 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.48 ng/mL	Low HER2 expression (HER2+)
Method Description	The cytotoxic effect of Trastuzumab-SG3227 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing breast and gastric cancers. The potency of Trastuzumab-SG3227 was assessed on the NCI-N87 cell line.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2130.00 ng/mL	Negative expression (HER2-)
Method Description	The cytotoxic effect of Trastuzumab-SG3227 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing breast and gastric cancers. The potency of Trastuzumab-SG3227 was assessed on the MDA-MB-468 cell line.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Engineered HER-SG3227 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.29 ng/mL	Low HER2 expression (HER2+)
Method Description	The cytotoxic effect of Engineered Her-SG3227 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing breast and gastric cancers. The potency of Engineered Her-SG3227 was assessed on the NCI-N87 cell line.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1220.00 ng/mL	Negative expression (HER2-)
Method Description	The cytotoxic effect of Engineered Her-SG3227 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing breast and gastric cancers. The potency of Engineered Her-SG3227 was assessed on the MDA-MB-468 cell line.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

References

Ref 1	Synthesis and in vitro evaluation of SG3227, a pyrrolobenzodiazepine dimer antibody-drug conjugate payload based on sibiromycin. Bioorg Med Chem Lett. 2017 Mar 1;27(5):1154-1158.